Plain-English translation of NCT04605146 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether weekly remote check-ins—simple questionnaires you complete at home—can help your doctor spot side effects from nivolumab and ipilimumab earlier than standard care alone. These two immunotherapy drugs work well against melanoma, lung, and kidney cancer, but they can cause significant side effects that need quick attention. The study wants to see if catching problems sooner leads to better outcomes.
About 30 to 60% of patients taking this medication experience serious side effects, and catching them early is critical for safe treatment. Right now, patients have routine office visits, but symptoms might go unreported between appointments. This trial is testing whether regular remote monitoring—without extra office visits—can close that gap and get you help faster.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly placed into one of two groups. Half the patients will receive standard care plus a year of weekly health questionnaires (sent by computer or phone), while the other half receives standard care alone. Both groups will be followed for up to 5 years to track how well the treatment works and your quality of life. You'll also fill out quality-of-life surveys at the start, 3 months, and 12 months.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
France